Action FTRP REUNION NEUROSCIENCE
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Reunion Neuroscience

Actions

FTRP

CA76134G1037

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Reunion Neuroscience Inc. Announces Advancing RE104, Its Proprietary, Clinical-Stage Serotonergic Psychedelic Drug Candidate to Provide Benefits to Patients with Underserved Mental Health Disorders
Reunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investors
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression
Reunion Neuroscience Brief: Reunion and MPM BioImpact Complete Plan of Arrangement Effective Today, whereby MPM Acquired Reunion in an all-cash transaction valued at Near US$13.1 million
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
Reunion Neuroscience Inc.(NasdaqGS:REUN) dropped from NASDAQ Composite Index
MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. in a going private transaction.
REUNION NEUROSCIENCE OBTAINS FINAL COURT ORDER FOR PROPOSED PLAN OF ARRANGEMENT
Reunion Neuroscience Gets Ontario Court's Final Approval for Acquisition by MPM BioImpact
Reunion Neuroscience Brief: Adds In "Assuming Remaining Conditions Precedent Are Satisfied Or Waived", Anticipates Closing of Arrangement Will Occur On Or About July 21, 2023
Reunion Neuroscience Brief: Says Obtained Final Court Order for Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Deal Valued at Near US$13.1 Million
Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
Reunion Neuroscience Brief: Arrangement remains subject to receipt of a final order of the Ontario Superior Court of Justice (Commercial List); Expected to be completed on or around July 21, 2023
Reunion Neuroscience Brief: Shareholders Approve Proposed Plan of Arrangement Whereby Affiliates of MPM BioImpact Will Buy REUN In An All-cash Tansaction Valued at Near US$13.1 Million
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement
Reunion Neuroscience : Annual Information Form For the Fiscal Year Ended March 31, 2023 - Form 6-K
Reunion Reports Q4 Results; Shareholders to Get US$1.12 Cash Per Share From Arrangement Agreement with MPM BioImpact
Reunion Neuroscience Brief: Adds It Presented "Encouraging" Phase 1 Final Analysis at American Society of Clinical Psychopharmacology Annual Meeting
Reunion Neuroscience Brief: Common Holders to Receive Consideration of US$1.12 Per Share in Cash from Arrangement Agreement with MPM BioImpact; Special Shareholder Meeting Scheduled July 12
Reunion Neuroscience Brief: Says incurred a net loss from continuing operations of $6.5 million or $0.56 per share and $38.1 million or $3.28 per share for the three and 12 month periods ended March 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action FTRP
  4. Actualités Reunion Neuroscience
  5. Autres langues